In this work we tried to develop new dopaminergic ligands with novel affinity and selectivity profile towards the five different dopamine receptor subtypes; namely D1, D2, D3, D4, and D5 receptors to come up with new medical agents but with fewer side effects relative to those present in the medicinal…